XML 12 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jul. 31, 2015
Jul. 31, 2014
Net revenue $ 2,822 $ 1,912
Sales and marketing costs (1,029) (1,034)
Stock- based compensation expense (775) (808)
Personalized Oncology Solutions [Member]    
Net revenue 485 341
Direct cost of services (634) (753)
Sales and marketing costs (332) (451)
Other operating expenses 0 0
Stock- based compensation expense [1] 0 0
Segment loss (481) (863)
Translational Oncology Solutions [Member]    
Net revenue 2,337 1,571
Direct cost of services (1,588) (963)
Sales and marketing costs (577) (428)
Other operating expenses (933) (1,318)
Stock- based compensation expense [1] 0 0
Segment loss (761) (1,138)
Unallocated Corporate Overhead [Member]    
Net revenue 0 0
Direct cost of services 0 0
Sales and marketing costs 0 0
Other operating expenses (880) (920)
Stock- based compensation expense [1] (775) (808)
Segment loss (1,655) (1,728)
Consolidated [Member]    
Net revenue 2,822 1,912
Direct cost of services (2,222) (1,716)
Sales and marketing costs (909) (879)
Other operating expenses (1,813) (2,238)
Stock- based compensation expense [1] (775) (808)
Segment loss $ (2,897) $ (3,729)
[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.